Clinical Trial Update: Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study evaluating darapladib in subjects with moderate hepatic impairment in the context of atherosclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Darapladib (darapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 1 | Status: COMPLETED